Table 1.
Baseline Characteristics: Demographic/ Enrollment Information/ Baseline CD4 Counts/ Percentages and HIV-1 RNA copies/mL
| Characteristic | Placebo (N=25) | 20 μg/kg (N=25) | 40 μg/kg (N=25) | 60 μg/kg (N=24) | Total (N=99) |
|---|---|---|---|---|---|
| Age, y Mean (s.d.) | 48 (8) | 50 (9) | 47 (10) | 51 (9) | 49 (9) |
| Sex, no. (%) | |||||
| Male | 22 (88%) | 23 (92%) | 22 (88%) | 23 (96%) | 90 (91%) |
| Female | 3 (12%) | 2 (8%) | 3 (12%) | 1 (4%) | 9 (9%) |
| Race/ethnicity, no. (%)* | |||||
| White non-Hispanic | 15 (60%) | 13 (52%) | 12 (50%) | 12 (50%) | 52 (53%) |
| Black non-Hispanic | 6 (24%) | 9 (36%) | 4 (17%) | 6 (25%) | 25 (26%) |
| Hispanic (regardless of race) | 3 (12%) | 3 (12%) | 8 (33%) | 6 (25%) | 20 (20%) |
| Asian, Pacific Islander | 1 (4%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) |
| CD4+ cell count, cells/mm3 Median (Q1-Q3) | 147 (110-180) | 155 (126-194) | 156 (116-197) | 152 (112-192) | 153 (116-194) |
| CD4+ cell percentages of all lymphocytes Median (Q1-Q3) | 12 (9-16) | 13 (12-16) | 11 (9-17) | 10 (8-16) | 12 (9-16) |
| HIV-1 RNA, copies/mL, no. (%)* | |||||
| ≥50 | 3 (12%) | 3 (12%) | 1 (4%) | 0 (0%) | 7 (7%) |
| <50 | 22 (88%) | 22 (88%) | 23 (96%) | 24 (100%) | 91 (93%) |
*
One subject declined to report race/ethnicity and one subject missed entry HIV-1 RNA evaluation.